WHO Raises Concern Over Acute Lack of Obesity Injections
Fewer than one in 10 individuals that would benefit from obesity jabs including Wegovy are able to get them, states the global health agency as it publishes its inaugural advice on the drugs.
Given in excess of 1,000,000,000 people worldwide now classified as obese, it is urging increased and just availability to GLP-1 medication.
Per estimates, more than two billion will be living with obesity by 2030 unless action is taken.
"The latest guidelines affirms that excess weight is a lifelong illness that can be treated with holistic and continuous treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are significant barriers to widespread access to the treatments that can help people shift significant body mass, says the agency.
GLP-1 Therapy Shortage
Even under the present best projected scenario, the supply of GLP-1 therapies might only reach about 100 million people – under 10% of those who need them, according to the health organization.
The recommendation calls on countries and companies to widen access, via approaches such as licensing agreements.
Exclusive production rights on the active ingredient – the core ingredient of Novo Nordisk's Wegovy – is scheduled to end in a number of nations in 2026.
The Way Weight-Loss Injections Work
The injections replicate a body's own hormone to reduce digestion speed, curb appetite and increase the sense of being full so individuals eat less.
People typically start to lose weight after several weeks of starting on the once-weekly jabs.
Studies suggests users may regain a significant portion after a year of stopping the medication, as their typical appetite return.
Being carrying excess weight increases your risk for experiencing health problems, including diabetes, heart disease, stroke, and specific malignancies.
Excess weight affects people in all nations and was associated with millions of deaths worldwide in 2024, as per the health agency.
